pubmed-article:18398152 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C1521808 | lld:lifeskim |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C1513884 | lld:lifeskim |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C0078058 | lld:lifeskim |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C0033681 | lld:lifeskim |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C0079083 | lld:lifeskim |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C1171892 | lld:lifeskim |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C1541530 | lld:lifeskim |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C0332173 | lld:lifeskim |
pubmed-article:18398152 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
pubmed-article:18398152 | pubmed:issue | 11 | lld:pubmed |
pubmed-article:18398152 | pubmed:dateCreated | 2008-4-9 | lld:pubmed |
pubmed-article:18398152 | pubmed:abstractText | AZD2171 is a potent inhibitor of vascular endothelial growth factor receptors that showed broad antitumor activity in preclinical models. Doses of up to 45 mg/d of AZD2171 are tolerable when administered alone. This study evaluated escalating doses of AZD2171 in combination with standard chemotherapy in patients with advanced non-small-cell lung cancer. | lld:pubmed |
pubmed-article:18398152 | pubmed:language | eng | lld:pubmed |
pubmed-article:18398152 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18398152 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:18398152 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18398152 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18398152 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18398152 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18398152 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18398152 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18398152 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:18398152 | pubmed:month | Apr | lld:pubmed |
pubmed-article:18398152 | pubmed:issn | 1527-7755 | lld:pubmed |
pubmed-article:18398152 | pubmed:author | pubmed-author:FRYDD | lld:pubmed |
pubmed-article:18398152 | pubmed:author | pubmed-author:SeymourLesley... | lld:pubmed |
pubmed-article:18398152 | pubmed:author | pubmed-author:ShepherdFranc... | lld:pubmed |
pubmed-article:18398152 | pubmed:author | pubmed-author:TuDongshengD | lld:pubmed |
pubmed-article:18398152 | pubmed:author | pubmed-author:ArnoldAndrewA | lld:pubmed |
pubmed-article:18398152 | pubmed:author | pubmed-author:RobertsonJane... | lld:pubmed |
pubmed-article:18398152 | pubmed:author | pubmed-author:LaurieScott... | lld:pubmed |
pubmed-article:18398152 | pubmed:author | pubmed-author:WalshWendyW | lld:pubmed |
pubmed-article:18398152 | pubmed:author | pubmed-author:PuchalskiThom... | lld:pubmed |
pubmed-article:18398152 | pubmed:author | pubmed-author:EllisPeter... | lld:pubmed |
pubmed-article:18398152 | pubmed:author | pubmed-author:PowersJeanJ | lld:pubmed |
pubmed-article:18398152 | pubmed:author | pubmed-author:GossGlenwoodG | lld:pubmed |
pubmed-article:18398152 | pubmed:author | pubmed-author:GauthierIsabe... | lld:pubmed |
pubmed-article:18398152 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:18398152 | pubmed:day | 10 | lld:pubmed |
pubmed-article:18398152 | pubmed:volume | 26 | lld:pubmed |
pubmed-article:18398152 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:18398152 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:18398152 | pubmed:pagination | 1871-8 | lld:pubmed |
pubmed-article:18398152 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:meshHeading | pubmed-meshheading:18398152... | lld:pubmed |
pubmed-article:18398152 | pubmed:year | 2008 | lld:pubmed |
pubmed-article:18398152 | pubmed:articleTitle | Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. | lld:pubmed |
pubmed-article:18398152 | pubmed:affiliation | The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa ON K1H 8L6, Canada. slaurie@ottawahospital.on.ca | lld:pubmed |
pubmed-article:18398152 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:18398152 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:18398152 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18398152 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18398152 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18398152 | lld:pubmed |